Keiichi Masuya
Overview
Explore the profile of Keiichi Masuya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ikeda K, Maezawa Y, Yonezawa T, Shimizu Y, Tashiro T, Kanai S, et al.
Front Chem
. 2023 Jan;
10:1090643.
PMID: 36700083
Protein-protein interactions (PPIs) are recognized as important targets in drug discovery. The characteristics of molecules that inhibit PPIs differ from those of small-molecule compounds. We developed a novel chemical library...
2.
Kurasaki H, Nagaya A, Kobayashi Y, Matsuda A, Matsumoto M, Morimoto K, et al.
Org Lett
. 2020 Oct;
22(20):8039-8043.
PMID: 33006475
Sustainable and efficient manufacturing methods for -methylated peptides remain underexplored despite growing interest in therapeutic -methylated peptides within the pharmaceutical industry. A methodology for the coupling of -terminally unprotected -methylamino...
3.
Kallen J, Izaac A, Chau S, Wirth E, Schoepfer J, Mah R, et al.
ChemMedChem
. 2019 May;
14(14):1305-1314.
PMID: 31066983
Hdm2 (human MDM2, human double minute 2 homologue) counteracts p53 function by direct binding to p53 and by ubiquitin-dependent p53 protein degradation. Activation of p53 by inhibitors of the p53-Hdm2...
4.
Vaupel A, Holzer P, Ferretti S, Guagnano V, Kallen J, Mah R, et al.
Bioorg Med Chem Lett
. 2018 Sep;
28(20):3404-3408.
PMID: 30217415
Small molecule inhibitors of the p53-MDM2 protein complex are under intense investigation in clinical trials as anti-cancer agents, including our first generation inhibitor NVP-CGM097. We recently described the rational design...
5.
6.
Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, et al.
Elife
. 2016 Nov;
5.
PMID: 27852439
No abstract available.
7.
Furet P, Masuya K, Kallen J, Stachyra-Valat T, Ruetz S, Guagnano V, et al.
Bioorg Med Chem Lett
. 2016 Aug;
26(19):4837-4841.
PMID: 27542305
The p53-MDM2 interaction is an anticancer drug target under investigation in the clinic. Our compound NVP-CGM097 is one of the small molecule inhibitors of this protein-protein interaction currently evaluated in...
8.
Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, et al.
J Med Chem
. 2015 Jul;
58(16):6348-58.
PMID: 26181851
As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo...
9.
Gessier F, Kallen J, Jacoby E, Chene P, Stachyra-Valat T, Ruetz S, et al.
Bioorg Med Chem Lett
. 2015 Jul;
25(17):3621-5.
PMID: 26141769
Blocking the interaction between the p53 tumor suppressor and its regulatory protein MDM2 is a promising therapeutic concept under current investigation in oncology drug research. We report here the discovery...
10.
Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, et al.
Elife
. 2015 May;
4.
PMID: 25965177
Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy...